Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4013 A phase 3 randomised study of 177Lu-edotreotide or everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (LEVEL, GETNE-T2217)

Introduction: Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SSTR)-positive lung neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: García-Álvarez A, Garcia-Carbonero R, Anido U, Jimenez-Fonseca P, Del Olmo-García M,

Keywords: Lung NET, Peptide receptor radionuclide therapy,

#3781 Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) – Data from the national registry SEPTRALU

Introduction: PRRT is established in the treatment repertoire for advanced neuroendocrine neoplasms (NEN) expressing somatostatin receptors, without strong evidence for other factors influencing their activity.

Conference:

Presenting Author:

Authors: Bello P, Mitjavila Casanovas M, Jimenez-Fonseca P, Cabezas Agrícola J, Hernando Cubero J,

Keywords: 177Lu-DOTATATE, neuroendocrine tumor, PRRT, prognosis, radionuclide therapy, survival,

#3569 Outcomes of Streptozotocin (STZ)-based chemotherapy (CT) in patients with advanced pancreatic neuroendocrine tumors (pNETs): Data from the Spanish Taskforce of Neuroendocrine and Endocrine Tumors (GETNE) national registry (R-GETNE)

Introduction: STZ-based CT has been used for advanced pNETs with rapid growth, high tumor load or progression to somatostatin analogues (SSA). Evidence supporting use of STZ-based CT in pNET is mainly retrospective, and there is an unmet need of prospective trials in this setting. We present data from the R-GETNE regarding the use of STZ in spanish centers.

Conference:

Presenting Author:

Authors: Esteban-Villarrubia J, Hernando J, Garcia A, Jimenez-Fonseca P, Teulé A,

Keywords: Streptozotocin, Chemotherapy, pNET, GETNE, R-GETNE,

#3562 Prognostic factors in stage I-III adrenocortical cancer (ACC): Data of 230 patients from the ICARO_GETHI/SEEN registry

Introduction: The scientific evidence on adjuvant treatment of adrenocortical carcinoma (ACC) is scarce and based on a retrospective Italian-German series.

Conference:

Presenting Author: Jimenez-Fonseca P

Authors: Ballester I, Álvarez-Escolá C, Valdes N, Hernando J, Picon M,

Keywords: Adrenocortical cancer, Adjuvant treatment, Mitotane, Prognosis, Survival,

#3537 177Lu-DOTATATE (PRRT) in the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs) versus other tumors

Introduction: 177Lu-DOTATATE (PRRT) treatment is indicated in Spain in GEPNET but its activity in other somatostatin receptor-positive tumors is known.

Conference:

Presenting Author: Jimenez-Fonseca P

Authors: Jimenez-Fonseca P, Pubul V, Belló P, Riesco-Martinez M, Aller J,

Keywords: PRRT, NET, Somatostatin receptor-positive tumor, Survival,